Quetiapine Fumarate
FDA-approved product (tablet, oral), marketed as Quetiapine Fumarate, Seroquel, Seroquel Xr.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bipolar disorder
- Bipolar I disorder
- Bipolar II disorder
- Major depressive disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Diazepines, oxazepines, thiazepines and oxepines
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Quetiapine Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
NCT00208819 · start 2003-09
Registered record
- Registry ID
- NCT00208819
- Conditions
- Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia
- Interventions
- risperidone; quetiapine; olanzapine; divalproex
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2007-07
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSenile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; DementiaInterventionrisperidone; quetiapine; olanzapine; divalproexPhasePhase 4Registry statusCompletedQuetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT00237393 · start 2003-08
Registered record
- Registry ID
- NCT00237393
- Conditions
- PTSD
- Interventions
- Quetiapine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2007-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPTSDInterventionQuetiapine; PlaceboPhasePhase 4Registry statusCompletedA Comparative Study of New Medications for Psychosis in Adolescents
NCT00222495 · start 2002-08
Registered record
- Registry ID
- NCT00222495
- Conditions
- Psychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective Disorders
- Interventions
- quetiapine; olanzapine; risperidone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2006-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective DisordersInterventionquetiapine; olanzapine; risperidonePhaseNot applicableRegistry statusCompletedEffect of Quetiapine on Negative Symptoms and Cognition
NCT00305422 · start 2001-11
Registered record
- Registry ID
- NCT00305422
- Conditions
- Schizophrenia
- Interventions
- Quetiapine fumarate; Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-11
- Completion
- 2003-01
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionQuetiapine fumarate; RisperidonePhasePhase 3Registry statusCompletedCATIE- Schizophrenia Trial
NCT00014001 · start 2000-12
Registered record
- Registry ID
- NCT00014001
- Conditions
- Schizophrenia
- Interventions
- perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2004-12
- Enrolment
- 1,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionperphenazine; olanzapine; quetiapine; risperidone +3 morePhasePhase 4Registry statusCompleted